Fungi-Nail: The Name, the Image, the Affiliates

why was a product name treated as the advertising claim itself?

A product's name counts as part of the claim, not just decoration above it. Under 21 CFR 101.93(g)(2)(iv), a statement becomes a disease claim when the disease effect comes through the product's name, its formulation, cited publications, disease terminology, or imagery, per the rule's text on govinfo. The name sits on the same list as the picture on the box.

The National Advertising Division, the ad industry's self-regulatory body, reached the same conclusion about Fungi-Nail Toe & Foot by a different route. NAD recommended Kramer Laboratories drop the name outright; Kramer disagreed, and the matter moved to the FTC. The Commission's February 28, 2018 resolution letter to NAD records that Kramer 'declined to follow NAD's recommendation to discontinue use of the product name Fungi-Nail Toe & Foot.'

Keeping a fungus-referencing name didn't doom the product — contrary to what most advertisers in this niche assume. The FTC closed the matter with the Fungi-Nail name unchanged once graphics, call-outs and a disclaimer were fixed. A name is one input into the claim, not an automatic disqualifier by itself, provided everything else around it stops pointing at the nail.

The name survived the case; the claims wrapped around it did not.

what did kramer change on the packaging to close the ftc matter?

Kramer rebuilt the packaging around one distinction: the skin beside the nail, not the nail itself. To close the matter, per the FTC's resolution letter, the company 'modified toenail graphics to depict a healthy nail with fungal infection on the skin surrounding the nail or between the toes' — with the product now shown applied to the infected skin, not the nail itself. The remedy was built entirely from artwork and disclaimer text, not a name change or a recall.

The FTC closed the file without a penalty, a recall, or further action.

• Front-panel imagery redrawn to show a healthy nail and infected surrounding skin, with a user applying the product to the skin, not the nail
• "CURES Most Athlete's Foot" added in bold on the front panel
• A red call-out box added reading "STOPS SKIN FUNGUS AROUND NAILS"
• Side panel added: "Not for nail or scalp fungus"

which part of the nail is still sellable and which is not?

The skin around or between the toes is sellable for fungus claims; the nail itself is not, and hasn't been since 1993. 21 CFR 310.545(a)(22)(iii) places any topical antifungal drug carrying claims for use on the scalp or on the nails outside GRASE — generally recognized as safe and effective — per Cornell's text of the rule, which makes a nail-fungus claim on a topical an unapproved new drug automatically.

The nail-labeled exclusion is not a recent tightening; it is settled law that has held for more than three decades, and enforcement volume shows no sign of softening. FDA traces the rule to a September 2, 1993 final rule determining that certain topical antifungal labeling claims — for use on the scalp or on the nails — are not generally recognized as safe and effective, a finding codified at 21 CFR 310.545(a)(22)(iii) and effective from March 2, 1994. Under the CARES Act, that non-monograph status was carried forward automatically into the modern OTC drug order system as a standing administrative order, so no new rulemaking has ever been required to keep enforcing it, and FDA now typically charges violators under section 505G(a)(5) with misbranding under 502(ee) rather than reopening the underlying question.

We could not verify current US prevalence or buyer-age data for onychomycosis, the medical name for toenail fungus, in this pass — CDC's fungal-nail-infections page returned an access-denied response rather than the figures themselves. Confirming a market-size or age-skew number for this niche would mean pulling CDC's fungal disease statistics directly, rather than reusing a figure that circulates in supplement-industry content.

how did fda use a product photograph as evidence of intended use?

FDA read the picture on the bottle as labeling, exactly like the words beside it. In its April 7, 2026 warning letter to Chemco Corporation over 'PRO Nail FUNGUS KILLER,' the agency cited 'the image on the principal display panel (PDP) of the dropper dispensing the drug directly on the nail' as evidence the product was intended as a drug, per the Chemco warning letter — the principal display panel is simply the front-facing panel a shopper sees first.

The words on the same page did similar work independently: labeling describing application under the nail tip, plus a website line naming toenail fungus among the conditions treated. Either citation alone would likely have supported the drug finding; FDA cited both together.

A photo alone did the legal work words usually do.

why were amazon resellers pulled into the remediation?

Amazon resellers got pulled in because Kramer's own packaging fix would not reach listings it did not control. The FTC's resolution letter records that Kramer 'has represented that, although it does not engage affiliate advertisers, it has reached out to Amazon affiliates reselling its Fungi-Nail Toe & Foot product to provide the new packaging.' We read that line as the real scope of the remediation: not just Kramer's shelf, every shelf still carrying the old graphics.

The FTC required none of it.

Nothing in the resolution letter compelled that outreach — the Commission closed the file regardless. It recorded the outreach among the facts supporting closure anyway, which tells you what a completed remediation actually gets judged against: creative sitting downstream on a marketplace, not just the words on the brand's own site. The same downstream-listing exposure runs through FTC's first fake-review supplement case, where marketplace listings, not brand copy, carried the claim the Commission challenged.

what does that perimeter imply for an affiliate running the offer?

It means an affiliate running old creative is exposed even after the advertiser has cleaned up its own house. If you are running a nail-fungus offer built on a dropper-on-nail image or a "clear nails in weeks" promise, that creative is not neutral just because someone else designed it — whether you can be pursued individually for it is the question we work through in our note on affiliate FTC liability.

The stakes vary by how far the claim runs. A name and a picture, corrected in time, closed this case with no penalty at all; the same combination, left uncorrected and layered onto a specific disease claim, is what ended a supplement company outright in a case we reviewed separately. Your creative library is the variable that decides which outcome you get.

how should creative be reviewed when the image carries the claim?

Review the picture and the copy as one claim, not two, because FDA and NAD both did. We checked both enforcement documents behind this page for every place an image, not a sentence, carried the legal weight, and found it in each — the FTC's graphics remediation and FDA's PDP citation.

If your creative shows a dropper touching the nail, redraw it before FDA or NAD does it for you.

• Does the image show the product touching the nail, or the skin beside it?
• Does any copy pair "nail" or "toenail" with a cure, eliminate or stop verb?
• Does a dropper, applicator or brush appear aimed at the nail plate itself?
• Is there a "not for nail or scalp fungus" disclaimer anywhere the nail is pictured?

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Weight Loss Pill Just Approved: A Reference for Operators, Is Weight Loss Pills Covered by Insurance?, Do Weight Loss Clinics Offer Ozempic?, Do Weight Loss Pills from Hers Work?, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.